Short-term symptomatic treatment of acute exacerbations of OA, long-term symptomatic treatment of RA.
Dosage/Direction for Use
TabRA 15 mg/day. May be reduced to 7.5 mg/day. OA 7.5 mg/day. May be increased to 15 mg/day. Dialysis patient w/ severe renal failure Max: 7.5 mg/day.
Administration
May be taken with or without food: May be taken w/ meals if GI discomfort occurs.
Contraindications
Active peptic ulceration, severe hepatic insufficiency, non-dialysed severe renal insufficiency, GI bleeding, cerebrovascular bleeding or other bleeding disorders. Pregnancy or lactation. Childn & adolescents <15 yr.
Special Precautions
History of upper GI disease, dehydrated patients, those w/ CHF, hypovolemia, liver cirrhosis, nephrotic syndrome, overt renal disease, those on diuretic or anticoagulant therapy, end-stage renal failure, frail or debilitated patients.
Adverse Reactions
GI disturbances, anemia, pruritus, skin rash, lightheadedness, headache, oedema.
Increased risk of bleeding when used w/ other NSAIDs including salicylates, oral anticoagulants, ticlopidine, heparin, thrombolytics. Increases serum lithium levels. Increases haematologic toxicity of methotrexate. Diuretics (monitor renal function). Elimination enhanced by cholestyramine. Decreases effects pentoxifylline of antihypertensives. Increases nephrotoxicity of cyclosporin.
Sign Out
